Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 4:4:1-9.
doi: 10.2147/ppa.s8230.

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

Francesco Patti  1
Affiliations

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

Francesco Patti. Patient Prefer Adherence. .

Abstract

Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.

Keywords: adherence; adverse events; compliance; efficacy; interruption; management; multiple sclerosis; tolerability.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Factors leading to poor adherence to multiple sclerosis therapy.
See this image and copyright information in PMC

References

    1. World Health Org. Adherence to long-term therapies. URL: http://www.who.int/chp/knowledge/publications/adherence_report/en/index..... Accessed Feb 26, 2007.
    1. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–6561. - PubMed
    1. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19:31–41. - PubMed
    1. Who gets MS? URL: http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/in.... Accessed May 21, 2009.
    1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability Brain 1989112(Pt 1):133–146. - PubMed